Reviewing Apyx Medical (NASDAQ:APYX) and Abiomed (NASDAQ:ABMD)
Reviewing Apyx Medical (NASDAQ:APYX) and Abiomed (NASDAQ:ABMD)
Apyx Medical (NASDAQ:APYX – Get Rating) and Abiomed (NASDAQ:ABMD – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.
阿皮克斯医疗(纳斯达克：APYX-GET评级)和艾彼德(纳斯达克：ABMD-GET评级)都是医疗公司，但哪一家更好？我们将根据两家公司的分析师建议、机构持股、盈利能力、估值、风险、股息和收益的强弱对它们进行比较。
Institutional and Insider Ownership
机构和内部人持股
65.6% of Apyx Medical shares are owned by institutional investors. Comparatively, 94.5% of Abiomed shares are owned by institutional investors. 11.6% of Apyx Medical shares are owned by company insiders. Comparatively, 2.5% of Abiomed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Apyx Medical 65.6%的股份由机构投资者持有。相比之下，Abied 94.5%的股份由机构投资者持有。Apyx Medical 11.6%的股份由公司内部人士持有。相比之下，Abied 2.5%的股份由公司内部人士持有。强大的机构持股表明，捐赠基金、大型基金经理和对冲基金相信，从长期来看，一只股票的表现将好于大盘。
Risk and Volatility
风险和波动性
Apyx Medical has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Abiomed has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
Apyx Medical的贝塔系数为1.3，表明其股价的波动性比标准普尔500指数高30%。相比之下，Abied的贝塔系数为1.4，这表明其股价的波动性比标准普尔500指数高40%。
Analyst Recommendations
分析师建议
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Apyx Medical | 0 | 1 | 3 | 0 | 2.75 |
| Abiomed | 0 | 5 | 1 | 0 | 2.17 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 阿皮克斯医疗 | 0 | 1 | 3 | 0 | 2.75 |
| Abied | 0 | 5 | 1 | 0 | 2.17 |
Apyx Medical presently has a consensus target price of $6.00, indicating a potential upside of 72.91%. Abiomed has a consensus target price of $355.60, indicating a potential downside of 6.67%. Given Apyx Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Apyx Medical is more favorable than Abiomed.
Apyx Medical目前的共识目标价为6.00美元，潜在上行空间为72.91%。Abied的共识目标价为355.60美元，表明潜在下跌6.67%。鉴于Apyx Medical更强劲的共识评级和更高的可能上行空间，股票研究分析师显然认为Apyx Medical比Abied更有利。
Profitability
盈利能力
This table compares Apyx Medical and Abiomed's net margins, return on equity and return on assets.
此表比较了Apyx Medical和Abied的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Apyx Medical | -39.28% | -39.82% | -31.06% |
| Abiomed | 24.84% | 14.77% | 13.32% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 阿皮克斯医疗 | -39.28% | -39.82% | -31.06% |
| Abied | 24.84% | 14.77% | 13.32% |
Earnings and Valuation
收益和估值
This table compares Apyx Medical and Abiomed's top-line revenue, earnings per share and valuation.
此表比较了Apyx Medical和Abied的营收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Apyx Medical | $48.52 million | 2.47 | -$15.17 million | ($0.56) | -6.20 |
| Abiomed | $1.03 billion | 16.65 | $136.51 million | $5.82 | 65.47 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 阿皮克斯医疗 | 4,852万美元 | 2.47 | -1,517万元 | ($0.56) | -6.20 |
| Abied | 10.3亿美元 | 16.65 | 1.3651亿美元 | $5.82 | 65.47 |
Abiomed has higher revenue and earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.
Abied的收入和收益比Apyx Medical更高。Apyx Medical的市盈率低于Abied，表明它目前是两只股票中更负担得起的一只。
Summary
摘要
Abiomed beats Apyx Medical on 10 of the 14 factors compared between the two stocks.
Abied在两只股票比较的14个因素中有10个超过了Apyx Medical。
About Apyx Medical
关于阿皮克斯医疗公司
(Get Rating)
(获取评级)
Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.
阿皮克斯医疗公司是一家以能源为基础的医疗技术公司。该公司致力于开发、制造和营销一系列电外科产品和技术，以及用于世界各地医生、手术中心和医院办公室的相关医疗产品。它通过以下部门运营：先进能源和原始设备制造(OME)。该公司由安德鲁·马克里德斯于1978年创立，总部设在佛罗里达州克利尔沃特。
About Abiomed
关于Abied
(Get Rating)
(获取评级)
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
Abied，Inc.从事医疗设备的研究、开发和销售，以帮助或取代衰竭心脏的泵浦功能。它还为心力衰竭患者提供持续的护理。该公司提供Impella 2.5，这是一种集成了发动机和传感器的经皮微型心脏泵；Impella CP，一种供介入心脏科医生在导管实验室支持患者以及心脏外科医生在心脏外科套件中使用的设备。它还提供Impella 5.0、Impella LD和Impella 5.5，这是一种具有集成电机和传感器的经皮微创心脏泵，主要用于心脏手术室；Impella RP是一种基于经皮导管的轴流泵；Impella SmartAssist平台包括光学传感器技术，可以改进泵的定位，并使用算法来改进断奶过程中的本地心脏评估；Impella Connect是一种基于云的技术，可以为医生和医院工作人员安全地远程查看自动Impella控制器；以及Oxy-1 System，这是一种便携式外部呼吸辅助设备。此外，该公司正在开发Impella ECP，这是一种每分钟血流超过3升的泵；Impella XR Sheath，一种可以膨胀和回缩的鞘，允许小孔进入，并与Impella心脏泵一起关闭；Impella BTR，一种集成了发动机和传感器的经皮微型心脏泵；以及PreCARDIA，一种导管安装的上腔静脉治疗系统，旨在快速治疗急性失代偿性心力衰竭。Abied，Inc.通过直销和临床支持人员在德国、法国、美国、日本、欧洲、加拿大、拉丁美洲、亚太地区和中东销售其产品。该公司成立于1981年，总部设在马萨诸塞州丹佛斯。截至2022年12月22日，Abied, 股份有限公司是强生的子公司。
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿皮克斯医学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Apyx Medical和相关公司的最新新闻和分析师评级的每日简要摘要。